Loading…

Loading grant details…

Completed HORIZON European Commission

Hormone-free solution for vaginal atrophy

€3.81M EUR

Funder European Commission
Recipient Organization Aveta Medical Limited
Country Ireland
Start Date Apr 01, 2022
End Date Dec 31, 2024
Duration 1,005 days
Number of Grantees 1
Roles Coordinator
Data Source European Commission
Grant ID 190178595
Grant Description

Vaginal Atrophy (VA) is a chronic and progressive condition. VA impacts on the quality of life, relationships, everyday activities and confidence of women sufferers. It is associated with thinning, drying and inflammation of the vaginal tissue. It is experienced by 80% of all women globally and is the most common symptom of the menopause.

Over 70% of Breast Cancer Survivors will also suffer from VA due to side effects of chemotherapy and the cancer-blocker drugs they take further exacerbate symptoms of VA. Current treatment options for VA, primarily pharmaceuticals are either ineffective or poorly tolerated. In the EU and US, 3.6m patients of VA reject existing treatments.

AVeta- a medical device delivering the only hormone free, affordable and safe targeted therapy for all women suffering from VA.

Solution is based on pathophysiology of wound healing and will be prescribed by a Clinician in an outpatient setting and women will self-administer the therapy monthly at home.

All Grantees

Aveta Medical Limited

Advertisement
Discover thousands of grant opportunities
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant